July 10, 2025, United States — After undergoing a year-long review and examination, the U.S. Food and Drug Administration (FDA) recently announced that five vape products from Juul Labs Inc. have officially received market sales authorization (Marketing Authorization, MGO), marking the long-awaited return of this once-troubled vape giant to the legal market, which had faced significant challenges due to health controversies.
According to the latest “July 2025 Vape Product Approval List” published on the FDA’s official website, the products authorized for sale include:
- JUUL Device (Vape Device)
- JUULpods [Menthol 3.0%]
- JUULpods [Menthol 5.0%]
- JUULpods [Virginia Tobacco 3.0%]
- JUULpods [Virginia Tobacco 5.0%]
This move is seen as a significant adjustment in the FDA’s regulatory policy for the vape industry, and also indicates that Juul is trying to regain consumer trust through a compliance-oriented approach.
Market Changes Behind Regulatory Review
In 2024, the FDA intensified its regulatory oversight of the vape market, requiring manufacturers to submit more rigorous safety and health data. Juul had previously faced lawsuits and public criticism from multiple states over issues such as “high youth usage rates” and “health risks,” leading to some retailers removing its products from shelves.
The five products approved by the FDA all meet the new safety and labeling requirements, including restrictions on underage access and clear health warnings. Analysts point out that this approval may be a compromise by the FDA between “adult smokers’ replacement needs” and “youth protection.”
Juul’s “Compliance Transformation” Journey
Since 2022, Juul has been fully implementing an “adult user-oriented” strategy, including:
- Limiting product packaging and advertising content
- Removing some flavor options
- Strengthening user age verification mechanisms
- Collaborating with public health organizations to conduct educational programs
This FDA approval is seen as a Phased victory for Juul’s “compliance transformation” strategy.However, industry insiders point out that Juul still faces long-term challenges from the market and regulators, including how to maintain competitiveness within the compliance framework and respond to ongoing public concerns about the health risks of its products.
Market Reaction and Future Outlook
Juul’s third-quarter 2024 financial report showed that due to market restrictions, the company’s revenue fell by more than 20%. This approval may help it regain some market share, but whether it can fully recover remains to be seen.
Meanwhile, other vape brands are also actively seeking FDA approval, and the competitive landscape is likely to become even more intense. The FDA stated that it will continue to conduct strict reviews on market access for vape products to ensure consumer safety
